Literature DB >> 10681718

Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.

E Knaust1, A Porwit-MacDonald, A Gruber, D Xu, C Peterson.   

Abstract

BACKGROUND AND
OBJECTIVE: Pharmacologic studies on blasts from patients with leukemia are generally performed on density gradient isolated blood or bone marrow cells. Thereby, cellular drug accumulation and efflux are determined as mean values of the entire cell population. The objective of the present study was to characterize the heterogeneity in the accumulation and efflux of daunorubicin in various subpopulations of mononuclear cells isolated from patients with acute myeloid leukemia (AML). DESIGN AND METHODS: Mononuclear cells from 33 patients with AML were isolated from peripheral blood by density gradient centrifugation on Lymphoprep (1. 077 g/mL). Cellular accumulation of fluorescent daunorubicin was determined by flow cytometry after incubation of the cells at +37C for 1 hour. Thereafter, the cells were washed and reincubated in drug-free medium. Kinetics of drug efflux were determined by frequent determination of cellular fluorescence during 30 min. Daunorubicin accumulation and efflux were compared in the total isolated mononuclear cell population and in the various blast cell populations gated on FSC/SSC according to the results of immunophenotyping.
RESULTS: In 8 of these 33 (24%) patient samples, two distinct blast cell populations could be identified. In 7 out of 8 these cases the more immature blasts had a lower drug accumulation and in 6 out of the 8 cases also a higher efflux rate than the differentiating cell population. Cyclosporin A increased daunorubicin accumulation and reduced efflux in the immature blast population. In the differentiating cell population cyclosporin A increased both the accumulation and the efflux. In patients with a single blast cell population, the gated blast cells had a significantly lower drug accumulation but also a lower drug efflux rate than the total cell population. INTERPRETATION AND
CONCLUSIONS: The results imply that drug transport studies on cells isolated from patients with AML give somewhat different results depending on the cell population studied. Some, but not all, of these differences in daunorubicin accumulation and efflux as well as in the effect of cyclo-sporin A can be explained by a heterogenous expression of the mdr1-gene. The observed heterogeneity may be of special relevance with regard to drug resistance. The presence of even a small resistant cell clone may jeopardize the effect of the chemotherapy due to expansion resulting in relapse of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681718

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.

Authors:  Andre Levchenko; Bipin M Mehta; Xinle Niu; Grace Kang; Liliana Villafania; Denise Way; Dolores Polycarpe; Michel Sadelain; Steven M Larson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

2.  Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs.

Authors:  Wei-Xian Chen; Yan-Qin Cai; Meng-Meng Lv; Lin Chen; Shan-Liang Zhong; Teng-Fei Ma; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2014-06-27

3.  Prediction of heterogeneous differential genes by detecting outliers to a Gaussian tight cluster.

Authors:  Zihua Yang; Zhengrong Yang
Journal:  BMC Bioinformatics       Date:  2013-03-05       Impact factor: 3.169

4.  Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.

Authors:  Wei-xian Chen; Xue-min Liu; Meng-meng Lv; Lin Chen; Jian-hua Zhao; Shan-liang Zhong; Ming-hua Ji; Qing Hu; Zhou Luo; Jian-zhong Wu; Jin-hai Tang
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.